Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016


  • Products Id :- GDHC3976CTIDB
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview of Alpha- Antitrypsin Deficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha- Antitrypsin Deficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Countries Contributing to Clinical Trials in Central and South America 12

Clinical Trials by G7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials 13

Clinical Trials by Phase in G7 Countries 14

Clinical Trials in G7 Countries by Trial Status 15

Clinical Trials by E7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials 16

Clinical Trials by Phase in E7 Countries 17

Clinical Trials in E7 Countries by Trial Status 18

Clinical Trials by Phase 19

In Progress Trials by Phase 20

Clinical Trials by Trial Status 21

Clinical Trials by End Point Status 22

Subjects Recruited Over a Period of Time 23

Clinical Trials by Sponsor Type 24

Prominent Sponsors 25

Top Companies Participating in Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials 26

Prominent Drugs 28

Latest Clinical Trials News on Alpha- Antitrypsin Deficiency 29

Dec 02, 2016: The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency 29

Nov 14, 2016: Arrowhead Pharmaceuticals Presents New Data on ARC-AAT 29

Oct 20, 2016: Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting 30

Clinical Trial Profile Snapshots 31

Appendix 58

Abbreviations 58

Definitions 58

Research Methodology 59

Secondary Research 59

About GlobalData 60

Contact Us 60

Disclaimer 60

Source 61

List of Figures

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 12

Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, G7 Countries (%), 2016* 13

Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14

Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15

Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016* 16

Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17

Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Phase (%), 2016* 19

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 20

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23

Alpha- Antitrypsin Deficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

GlobalData Methodology 59

List of Tables

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Region, 2016* 6

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, North America, Top Countries, 2016* 11

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12

Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, G7 Countries (%), 2016* 13

Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14

Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15

Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016* 16

Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17

Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Phase, 2016* 19

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 20

Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23

Alpha- Antitrypsin Deficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Grifols SA, Shire Plc, Kamada Ltd, CSL Ltd, Bayer AG, Applied Genetic Technologies Corp, ICON Plc, Alnylam Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Arriva Pharmaceuticals Inc

Alpha- Antitrypsin Deficiency Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Alpha- Antitrypsin Deficiency, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

select a license
Single User License
USD 2500 INR 179475
Site License
USD 5000 INR 358950
Corporate User License
USD 7500 INR 538425

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com